Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Digestive Diseases and Sciences|March 3, 2017
Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort StudyMaria Kalafateli, Konstantinos Zisimopoulos, Georgia Vourli, et al.Annals of Gastroenterology|September 4, 2018
Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysisHariklia Kranidioti, Christina Chatzievagelinou, Adonis Protopapas, et al.Journal of Hepatology|September 9, 2014
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirGeorge V Papatheodoridis, George N Dalekos, Cihan Yurdaydin, et al.Alimentary Pharmacology & Therapeutics|June 23, 2022
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risksGeorge V Papatheodoridis, Kostas Mimidis, Spilios Manolakopoulos, et al.Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.Journal of Hepatology|February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationGeorge V Papatheodoridis, Vana Sypsa, George Dalekos, et al.Hepatology (Baltimore, Md.)|June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BGeorge V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.Journal of Hepatology|January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.Pageof 4